688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
- 8.43
- -0.22-2.54%
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. News
Fudan Zhangjiang Voluntary Disclosure Notice Concerning Acceptance of Drug Marketing Applications for Obecholic Acid Tablets to Treat Primary Biliary Cholangitis
Fudan and Zhangjiang voluntarily disclosed an announcement on the completion of the US Phase II clinical trial of injectable hempofen to treat erythematous moles
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. voluntarily disclosed an announcement regarding the completion of the enrollment of the first subject in the phase III clinical trial of the injection of FDA018 antibody conjugate for the treatment of triple-negative breast cancer.
Announcement from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Regarding the Resignation of Core Technical Personnel
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd voluntarily disclosed the announcement of completing the first subject enrollment in Phase I clinical trial for injection of FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.
Rules of Procedures of the Board of Directors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
Announcement of resolutions from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.'s 2023 Shareholders' Annual Meeting.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. voluntarily disclosed the completion of the first subject's enrollment in the Verification Clinical Trial of Oral Amantadine Hydrochloride Powder for Visualizing Glioma Surgery.
Announcement of the Progress of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.'s Termination of Promotion Service Agreement with Shanghai Huizheng.
Fudan Zhangjiang Notice on Convening the 2023 Annual General Meeting of Shareholders
Fudan Zhangjiang 2023 Annual General Meeting of Shareholders Meeting Materials
Fudan Zhangjiang Notice on Response to the 2023 Annual Report Information Disclosure Regulatory Inquiry Letter
Fudan Zhangjiang Announcement on Requesting the Shareholders' Meeting to Authorize the Board of Directors to Issue Shares to Specific Targets through Simple Procedures
Announcement of Fudan and Zhangjiang on preparing for asset impairment
Fudan Zhangjiang 2023 Internal Control Evaluation Report
Fudan Zhangjiang 2024 “Improve Quality, Increase Efficiency, and Reward” Action Plan
Announcement of Fudan and Zhangjiang on revising the “Articles of Association” and formulating and revising some rules and systems
Rules of procedure for the Audit Committee of the Board of Directors of Fudan Zhangjiang
Rules of Procedure for the Nomination Committee of the Board of Directors of Fudan Zhangjiang
Rules of procedure for the Remuneration Committee of the Board of Directors of Fudan Zhangjiang
No Data
